Dairy Product Intake Modifies MicroRNA Expression among Individuals with Hyperinsulinemia: A Post-Intervention Cross-Sectional Study.


Journal

Lifestyle genomics
ISSN: 2504-3188
Titre abrégé: Lifestyle Genom
Pays: Switzerland
ID NLM: 101716139

Informations de publication

Date de publication:
2022
Historique:
received: 08 09 2021
accepted: 10 02 2022
pubmed: 28 2 2022
medline: 6 8 2022
entrez: 27 2 2022
Statut: ppublish

Résumé

MicroRNA (miRNA) profiles have been shown to change after intake of dairy products. Dysregulation of miRNA is associated with the changes in the level of glycemic parameters. The objectives are: (1) to investigate miRNA expression after consumption of dairy products and (2) to study the association between miRNAs and glycemic profile among individuals with hyperinsulinemia. In crossover design, 24 participants were randomized into 2 phases: high dairy (HD) (≥4 servings/day according to the Canadian food guide [2007]) and adequate dairy (AD) (≤2 servings/day) over 6 weeks. First, miRNAs were extracted from a pooled plasma sample of 10 subjects after HD and AD intervention which analyzed in duplicate by array hybridization (Affymetrix Gene Chip miRNA Array v. 4.0). Second, 6 miRNAs related to type 2 diabetes (T2D) were validated by quantitative reverse transcription polymerase chain reaction (qRT-PCR) from plasma of 24 participants. Microarray analysis indicated that 297 miRNAs expressed differentially (FC ≥ ±1.2; p value <0.05) in a pooled plasma sample of 10 subjects. Among pooled miRNAs, the level of selected miRNAs, including miR-652-3p, miR-106b-5p, miR-93-5p, and miR-107 were downregulated; conversely, miR-223-3p and miR-122-5p were upregulated. After qRT-PCR validation, only the expression level of miR-106-5p tended to be increased after HD compared to AD (p = 0.06). After AD intervention, the level of fasting plasma glucose (FPG) and insulin and homeostatic model assessment of insulin resistance were negatively correlated with miR-122-5p. Similarly, negative correlation was found between miR-106-5p and FPG. The miRNAs profile was modified after HD compared to AD, and this may have role in modifying the risk of T2D (registration No. NCT02961179).

Identifiants

pubmed: 35220313
pii: 000523809
doi: 10.1159/000523809
doi:

Substances chimiques

MicroRNAs 0

Banques de données

ClinicalTrials.gov
['NCT02961179']

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

77-86

Subventions

Organisme : CIHR
ID : PJT-364008
Pays : Canada

Informations de copyright

© 2022 The Author(s). Published by S. Karger AG, Basel.

Auteurs

Leila Khorraminezhad (L)

Endocrinology and Nephrology Unit, CHU de Québec-Laval University Research Center, Quebec, Québec, Canada.

Iwona Rudkowska (I)

Department of Kinesiology, Laval University, Quebec, Québec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH